Practical guide to the use of abiraterone in castration resistant prostate cancer.

Abstract

INTRODUCTION While androgen deprivation therapy remains the primary treatment modality for patients with metastatic prostate cancer, treatment is uniformly marked by progression to castration resistant prostate cancer (CRPC). Abiraterone is the first new drug to enter clinical practice in a series of novel agents designed to potently target adrenal and… (More)

Topics

2 Figures and Tables

Cite this paper

@article{Mostaghel2014PracticalGT, title={Practical guide to the use of abiraterone in castration resistant prostate cancer.}, author={Elahe A. Mostaghel and Daniel W. Lin}, journal={The Canadian journal of urology}, year={2014}, volume={21 2 Supp 1}, pages={57-63} }